Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernanda B Musa

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Annual Review of Medicine|January 27, 2026
Accessibility of Somatic Genetic Testing for Cancer Treatment DecisionsMadison Klavans, Fernanda B Musa, Marilyn Huang
Current Opinion in Obstetrics & Gynecology|January 8, 2025
State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025Fernanda B Musa, Kathleen N Moore, Vivek Podder, et al.
Gynecologic Oncology|January 15, 2022
Trends in treatment patterns and costs of care among patients with advanced stage cervical cancerFernanda B Musa, Elizabeth Brouwer, Jie Ting, et al.
Gynecologic Oncology|May 5, 2026
Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE studyFernanda B Musa, Tirza Areli Calderón Boyle, Jonathan T Lim, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Annual Review of Medicine|January 27, 2026
Accessibility of Somatic Genetic Testing for Cancer Treatment DecisionsMadison Klavans, Fernanda B Musa, Marilyn Huang
Current Opinion in Obstetrics & Gynecology|January 8, 2025
State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025Fernanda B Musa, Kathleen N Moore, Vivek Podder, et al.
Gynecologic Oncology|January 15, 2022
Trends in treatment patterns and costs of care among patients with advanced stage cervical cancerFernanda B Musa, Elizabeth Brouwer, Jie Ting, et al.
Gynecologic Oncology|May 5, 2026
Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE studyFernanda B Musa, Tirza Areli Calderón Boyle, Jonathan T Lim, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Pageof 1